Founded December 2017
Stage Technology development
Investor Trendlines Incubators Israel
CEO Nimrod Kaufmann
SetBone Medical is developing a novel acrylic-based bone augmentation cement for use in kyphoplasty procedures. Existing liquid/powder acrylic cements are plagued with limitations, including the release of toxic monomers, on-site mixing, cement inconsistency (viscosity), and potential tissue damage due to exothermic reaction.
SetBone’s novel cement solves these problems and offers surgical teams a safer and simpler approach to treating VCFs. The Company is developing a non-toxic acrylic bone cement packaged in a ready-to-use prefilled cartridge that immediately delivers a cement with constant viscosity that hardens (cures) when exposed to body temperature. It’s simple: no preparation needed, and viscosity stays constant until cement is exposed to body temperature. And it’s safer: no toxic monomers or exothermic reaction that could damage surrounding tissues.
Better handling
• Ready-to-use; no on-site preparation
Improved safety
• No free monomers; safe both for patient and surgical team
• Cement hardening only at body temperature
• Low exothermic reaction; reduced tissue damage
• Low shrinkage; improved fill and anchoring
2 National phase submissions
The market seeks a novel cement that overcomes the drawbacks of current liquid/powder acrylic cements for the treatment of vertebral compression fractures (VCFs). Osteoporosis leads to 1.5 million fractures each year in the United States, of which 750,000 are vertebral compression fractures (VCFs).
According to MedDeviceTracker, the global kyphoplasty and vertebroplasty market is expected to exceed $1 billion by 2023.
Founder and CEO, Inspiro Medical Ltd., acquired by Opko Health Inc.; 15+ years’ medical device and orthopedic implant development including the Confidence Bone Cement, acquired by Kyphon.; BSc, mechanical engineering, Ben-Gurion University of the Negev
Managerial and R&D experience developing polymeric-based products; PhD, physical chemistry, Weizmann Institute of Science; MA, biotechnology, Tel Aviv University
President and CEO, Collagen Solutions; over 25 years’ experience in the medical device field with M&A, commercial, and operational leadership
Fellowship-trained orthopedic surgeon at Texas Back Institute; researcher and advisor with 26 U.S. patents, 100+ publications, and 50+ book chapters
Expert in spinal neurosurgery; Deputy Director, Center for Spine Surgery, Assuta Medical Center, Tel Aviv; MD, Hebrew University of Jerusalem; former practice in neurosurgery of spine, Montefiore Medical Center, New York
Osteoporosis leads to 1.5 million fractures each year in the United States of which about 750,000 are collapsed vertebra or vertebral compression fractures (VCFs). Surgical intervention may be required when bed rest and medical treatment fail to reduce pain.
The two most common minimally invasive procedures to correct VCF are vertebroplasty and kyphoplasty. Both treatment options involve injecting bone cement into the fractured vertebra to stabilize the spine and prevent further deterioration. In kyphoplasty, an inflatable balloon is inserted into the vertebra prior to the injection of bone cement to create a cavity and restore disc height.
In the United States, more than 100,000 VCFs are treated with vertebroplasty and kyphoplasty. Unfortunately, in up to 52% of procedures, there is risk of cement leakage into the spinal canal, bloodstream, and disc space causing possible paraplegia, embolisms, and vertebral fractures (Journal of Medical Case Reports, Feb 2016).
In addition, the curing process (the time it takes for cement to set and harden) is extremely time sensitive. Physicians have about 5-10 minutes to complete the process of mixing the cement and accurately injecting it into the fractured vertebra before the mixture begins to harden.
Worldwide, approximately 20% of people over the age of 70, and 16% of postmenopausal women, suffer from vertebral compression fractures (Journal of Clinical and Diagnostic Research, Ballane, et al., August 2017).
According to MedDeviceTracker, the global kyphoplasty and vertebroplasty market is expected to exceed $1 billion by 2023.
